India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The greenhouse industry is entering 2026 with a complex wave of overlapping risks — from rising insurance costs and extreme weather to cyber threats, labor shortages, and unstable supply chains. These challenges aren’t isolated; they compound one another, increasing pressure on growers and business owners alike. Insights from industry experts reveal the key trends shaping risk management in the year ahead and what operators must do now to stay resilient.
New FDIC reporting rules are changing how banks classify and disclose commercial real estate loans, replacing the old Troubled Debt Restructuring label with clearer “financial difficulty” modifications and expanding transparency across structured products and capital requirements. These updates may briefly tighten lending but ultimately promise stronger liquidity, cleaner risk data, and more predictable CRE financing as banks adapt.
Artificial intelligence is no longer an upcoming trend—it's already reshaping how real estate professionals work, compete, and win. With the AI real estate sector set to surge from $222B in 2024 to nearly $1T by 2029, the industry is undergoing a rapid transformation in valuations, virtual tours, listings, investment analysis, and client management. Agents and investors who embrace AI tools are gaining unprecedented efficiency and insight, while those who resist risk falling behind.
The Federal Housing Finance Agency is weighing the idea of 50‑year mortgages, a move that could make monthly payments more affordable but dramatically increase total interest costs. Supporters say it may help young professionals break into the housing market, while critics warn it could trap families in half a century of debt. As the industry debates this controversial loan option, real estate and mortgage professionals must stay informed to guide clients through the shifting landscape.
December is shaping up to be another unpredictable month for mortgage rates. With the Federal Reserve signaling mixed messages, key economic reports running behind schedule, and lenders already looking ahead to 2026, rates could face upward pressure. Experts from Fannie Mae and the MBA project an average 30‑year rate around 6.3% for late 2025, suggesting a potential December bump. For real estate and mortgage professionals, understanding this volatility isn’t just helpful — it’s a competitive edge.
Sellers are cutting prices at record levels, delistings are surging to highs not seen since 2017, and buyers remain hesitant despite slightly lower mortgage rates. With affordability still strained and new construction slowing, the 2025 housing market is entering a deeper‑than‑usual winter slowdown marked by caution on all sides.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
